Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The multiple myeloma therapy market has witnessed considerable advances in recent years. Effective therapies such as Thalomid, Revlimid, Velcade, Pomalyst, and Kyprolis have transformed the treatment of this disease, and the treatment algorithms for multiple myeloma continue to evolve, driven by the 2015 approval of several novel, high-priced therapies with new mechanisms of action. This analysis provides insight on current and anticipated use of approved therapies for multiple myeloma and on hematologist-oncologists’ perception of these therapies.
Already a Client? Log in to access this report.